# Study of CPI-100 in Patients With Advanced Tumors

> **NCT03781362** · PHASE1 · COMPLETED · sponsor: **Coordination Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Advanced Tumors

## Interventions

- **DRUG:** CPI-100
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03781362
- **Lead sponsor:** Coordination Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781362, "Study of CPI-100 in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03781362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*